文献速递神经肿瘤

机构类型与手术量对低级别胶质瘤预后的影响

Impact of facility type and volume in low-grade glioma outcomes.
PubMed 文献 · J Neurosurg · 2019-09-27

该回顾性队列研究纳入国家癌症数据库5539例低级别胶质瘤患者(2004-2014),按机构类型(学术中心与非学术中心)和年手术量(高量与前1%与非高量)分组。高量机构和学术中心均显示生存优势(HR 0.67和0.84),且更常行肿瘤切除和化疗、住院时间更短。

要点

  • 高量机构治疗与更低死亡风险独立相关(HR 0.67)。
  • 学术中心治疗与生存获益相关(HR 0.84)。
  • 高量机构和学术中心更常实施切除和化疗,住院时间更短。

核心结论

  • 在高量机构和学术中心治疗的低级别胶质瘤患者具有生存获益。

研究设计与样本

  • 回顾性队列研究,纳入国家癌症数据库5539例低级别胶质瘤患者(2004-2014)。
  • 高量机构定义为年病例数前1%的机构。

主要发现

  • 高量机构总生存HR 0.67(95%CI 0.55-0.82,p<0.001)。
  • 学术中心总生存HR 0.84(95%CI 0.73-0.97,p=0.015)。
  • 高量机构相比非高量机构行肿瘤切除的可能性高41%,学术中心相比非学术中心高26%。
  • 高量机构相比非高量机构化疗使用频率高40%,学术中心相比非学术中心高88%。
  • 高量机构和学术中心住院时间延长分别减少42%和24%。

临床怎么用

  • 低级别胶质瘤患者可考虑在高量机构或学术中心接受治疗以改善预后。

局限性

  • 研究为回顾性设计,结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The object of this study was to investigate the impact of facility type (academic center [AC] vs non-AC) and facility volume (high-volume facility [HVF] vs low-volume facility [LVF]) on low-grade glioma (LGG) outcomes. METHODS: This retrospective cohort study included 5539 LGG patients (2004-2014) from the National Cancer Database. Patients were categorized by facility type and volume (non-AC vs AC, HVF vs LVF). An HVF was defined as the top 1% of facilities according to the number of annual cases. Outcomes included overall survival, treatment receipt, and postoperative outcomes. Kaplan-Meier and Cox proportional-hazards models were applied. The Heller explained relative risk was computed to assess the relative importance of each survival predictor. RESULTS: Significant survival advantages were observed at HVFs (HR 0.67, 95% CI 0.55-0.82, p < 0.001) and ACs (HR 0.84, 95% CI 0.73-0.97, p = 0.015), both prior to and after adjusting for all covariates. Tumor resection was 41% and 26% more likely to be performed at HVFs vs LVFs and ACs vs non-ACs, respectively. Chemotherapy was 40% and 88% more frequently to be utilized at HVFs vs LVFs and ACs vs non-ACs, respectively. Prolonged length of stay (LOS) was decreased by 42% and 24% at HVFs and ACs, respectively. After tumor histology, tumor pattern, and codeletion of 1p19q, facility type and surgical procedure were the most important contributors to survival variance. The main findings remained consistent using propensity score matching and multiple imputation. CONCLUSIONS: This study provides evidence of survival benefits among LGG patients treated at HVFs and ACs. An increased likelihood of undergoing resections, receiving adjuvant therapies, having shorter LOSs, and the multidisciplinary environment typically found at ACs and HVFs are important contributors to the authors' finding.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhu P, Du XL, Blanco AI, et al. Impact of facility type and volume in low-grade glioma outcomes. J Neurosurg. 2019. PMID: 31561219. doi:10.3171/2019.6.JNS19409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。